Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Gains from Sales and Divestitures: 2024-2025

Historic Gains from Sales and Divestitures for iSpecimen (ISPC) over the last 1 years, with Sep 2025 value amounting to $382.

  • iSpecimen's Gains from Sales and Divestitures fell 78.08% to $382 in Q3 2025 from the same period last year, while for Sep 2025 it was $382, marking a year-over-year decrease of 78.08%. This contributed to the annual value of $1,800 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, iSpecimen's Gains from Sales and Divestitures is $382, which was up 13.02% from $338 recorded in Q2 2025.
  • iSpecimen's Gains from Sales and Divestitures' 5-year high stood at $1,800 during Q4 2024, with a 5-year trough of $152 in Q1 2025.
  • Moreover, its 2-year median value for Gains from Sales and Divestitures was $382 (2025), whereas its average is $883.
  • Data for iSpecimen's Gains from Sales and Divestitures shows a maximum YoY plummeted of 78.08% (in 2025) over the last 5 years.
  • Over the past 2 years, iSpecimen's Gains from Sales and Divestitures (Quarterly) stood at $1,800 in 2024, then crashed by 78.08% to $382 in 2025.
  • Its Gains from Sales and Divestitures was $382 in Q3 2025, compared to $338 in Q2 2025 and $152 in Q1 2025.